Some perspective on the GLP-1 market #diabetes via @novonordisk Dulaglutide the leader, liraglutide slowly falling, semaglutide rising steadily novonordisk.com/content/dam/De Some perspective on the GLP-1 market #diabetes via @novonordisk Dulaglutide the leader, liraglutide slowly falling, semaglutide rising steadily novonordisk.com/content/dam/De On to #obesity where Liraglutide 3 mg daily remains the market leader Four interesting trials studying semaglutide
Importantly, its expression has been found to be increased in the CNS of human brains with HSE, as well as in those with neurodegenerative diseases (Jackson et al., 2006)
Existing evidence indicates that eating disorders can increase the risk of diabetes, obesity, hypertension, hypertriglyceridemia, headache, back pain, and other chronic metabolic diseases
Injections are simple, using a small insulin-type syringe, and most patients quickly become comfortable with the process